ArticlePloS one2014
Detection of circulating hcmv-miR-UL112-3p in patients with glioblastoma, rheumatoid arthritis, diabetes mellitus and healthy controls.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 41 citations in OpenAlex.
- Review
- Clinical implications of cytomegalovirus in glioblastoma progression and therapy.NPJ precision oncology · 2024Review
- The potential of miRNA-based approaches in glioblastoma: An update in current advances and future perspectives.Current research in pharmacology and drug discovery · 2024Review
- Viral miRNA regulation of host gene expression.Seminars in cell & developmental biology · 2023Review
- Human cytomegalovirus in cancer: the mechanism of HCMV-induced carcinogenesis and its therapeutic potential.Frontiers in cellular and infection microbiology · 2023Review
- Cytomegalovirus microRNAs level determination in kidney recipients post transplantation.Virology journal · 2022Article
- Cytomegalovirus-Specific Immunotherapy for Glioblastoma Treatments.Brain tumor research and treatment · 2022Review
- Altered serum human cytomegalovirus microRNA levels are common and closely associated with the inflammatory status in patients with fever.Frontiers in immunology · 2022Article
- Human Cytomegalovirus Induced Aberrant Expression of Non-coding RNAs.Frontiers in microbiology · 2022Review
- Human cytomegalovirus (HCMV)-encoded microRNAs: potential biomarkers and clinical applications.RNA biology · 2021Review
- Review
- Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs.Pathogens (Basel, Switzerland) · 2021Review
- Human Cytomegalovirus-Encoded microRNAs Can Be Found in Saliva Samples from Renal Transplant Recipients.Non-coding RNA · 2020Article
- Different expression pattern of human cytomegalovirus-encoded microRNAs in circulation from virus latency to reactivation.Journal of translational medicine · 2020Article
- Herpesviruses and MicroRNAs: New Pathogenesis Factors in Oral Infection and Disease?Frontiers in immunology · 2018Review
- Using NMR in saliva to identify possible biomarkers of glioblastoma and chronic periodontitis.PloS one · 2018Article
- Decreased human leukocyte antigen A*02:01 frequency is associated with risk of glioma and existence of human cytomegalovirus: a case-control study in Northern China.Cancer immunology, immunotherapy : CII · 2017Article
- Distinct expression profile of HCMV encoded miRNAs in plasma from oral lichen planus patients.Journal of translational medicine · 2017Article
- How does cytomegalovirus factor into diseases of aging and vaccine responses, and by what mechanisms?GeroScience · 2017Article
- Manipulation of Viral MicroRNAs as a Potential Antiviral Strategy for the Treatment of Cytomegalovirus Infection.Viruses · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundmicroRNAs (miRNA) are 18-22 nucleotides long non-coding RNAs that regulate gene expression at a post-transcriptional level. Human cytomegalovirus (HCMV) encodes at least 26 known mature miRNAs. hcmv-miR-UL112-3p (miR-UL112-3p) is the most well characterized HCMV miRNA, which is suggested to play role in establishment and maintenance of viral latency. Elevated miR-UL112-3p levels have been reported to be present in plasma of patients with hypertension.
objectivesIn this study, we aimed to quantify miR-UL112-3p levels in the plasma/serum of patients with Diabetes Mellitus (DM; from the DIGAMI-2 cohort), Glioblastoma multiforme (GBM), Rheumatoid Arthritis (RA) and Healthy Controls (HC). STUDY
designTotal RNA was isolated from plasma/serum samples of 87 patients and controls, a TaqMan miRNA assay was performed to detect miR-UL112-3p and the copy numbers were normalized to 10 ng of total RNA. HCMV IgG and IgM were analysed using ELISA.
resultsHCMV miR-UL112-3p was detected in 14/27 (52%) of DM, 5/20 (25%) of GBM, 1/20 (5%) of RA patients and in 2/20 (10%) of HC, respectively. Anti-HCMV IgG was detected in 85%, 65%, 75% of patients and 70% of HC, respectively. Anti-HCMV IgM was found only in one GBM patient of 87 examined patients and controls.
conclusionsA higher prevalence of miR-UL112-3p was detected in DM and GBM patients than in RA patients and HC. Elevated levels of miR-UL112-3p and higher prevalence of HCMV IgG were observed in DM patients. Whether the presence of circulating miR-UL112-3p denotes a biomarker of HCMV latency or active replication in patients warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.